Cortagen — EU research guide.

What is Cortagen?

Cortagen belongs to the family of short-sequence tetrapeptide bioregulators developed by Vladimir Khavinson's research group. These peptides are proposed to act as gene-expression modulators in specific tissues. Cortagen targets cardiovascular tissue — specifically vascular endothelium and cardiac muscle — with proposed effects on protein synthesis regulation.

What does the research show?

The majority of published research originates from Russian institutions and involves animal models and small human observational studies. Data suggests Cortagen supports endothelial function and reduces markers of vascular aging in aged animal models. Western peer-reviewed replication is limited. The evidence base is considered preliminary by international standards.

EU legal status

Cortagen is not registered as a medicine in the EU. It is available from specialist research vendors as a laboratory compound. The Russian bioregulator peptides as a class are research compounds outside Russia.